These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 38717936)
1. KIAA1429 regulates lung adenocarcinoma proliferation and metastasis through the PI3K/AKT pathway by modulating ARHGAP30 expression. Guo W; Wang T; Huai Q; Guo L; Wang X; He J Thorac Cancer; 2024 Jun; 15(18):1397-1409. PubMed ID: 38717936 [TBL] [Abstract][Full Text] [Related]
2. Gene amplification-driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A-YTHDF2-dependent in lung adenocarcinoma. Zhang C; Sun Q; Zhang X; Qin N; Pu Z; Gu Y; Yan C; Zhu M; Dai J; Wang C; Li N; Jin G; Ma H; Hu Z; Zhang E; Tan F; Shen H Cancer Commun (Lond); 2022 Jul; 42(7):609-626. PubMed ID: 35730068 [TBL] [Abstract][Full Text] [Related]
3. KIAA1429 Induces m6A Modification of LINC01106 to Enhance the Malignancy of Lung Adenocarcinoma Cells via the JAK/STAT3 Pathway. Xu D; Wang Z; Li F Crit Rev Immunol; 2024; 44(6):49-61. PubMed ID: 38848293 [TBL] [Abstract][Full Text] [Related]
4. KIAA1429 promotes the progression of lung adenocarcinoma by regulating the m6A level of MUC3A. Zhao W; Xie Y Pathol Res Pract; 2021 Jan; 217():153284. PubMed ID: 33249400 [TBL] [Abstract][Full Text] [Related]
5. Mex3a interacts with LAMA2 to promote lung adenocarcinoma metastasis via PI3K/AKT pathway. Liang J; Li H; Han J; Jiang J; Wang J; Li Y; Feng Z; Zhao R; Sun Z; Lv B; Tian H Cell Death Dis; 2020 Aug; 11(8):614. PubMed ID: 32792503 [TBL] [Abstract][Full Text] [Related]
6. KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m Lin X; Ye R; Li Z; Zhang B; Huang Y; Du J; Wang B; Meng H; Xian H; Yang X; Zhang X; Zhong Y; Huang Z Drug Resist Updat; 2023 Jan; 66():100908. PubMed ID: 36493511 [TBL] [Abstract][Full Text] [Related]
7. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway. Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942 [TBL] [Abstract][Full Text] [Related]
8. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway. Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133 [TBL] [Abstract][Full Text] [Related]
9. DUS4L suppresses invasion and metastasis in LUAD via modulation of PI3K/AKT and ERK/MAPK signaling through GRB2. Li Z; Zhao PL; Gao X; Li X; Meng YQ; Li ZQ; Zhai KR; Wei SL; Feng HM; Huang HR; Li B Int Immunopharmacol; 2024 Dec; 142(Pt A):113043. PubMed ID: 39216120 [TBL] [Abstract][Full Text] [Related]
10. Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway. Zhu HE; Yin JY; Chen DX; He S; Chen H Cell Death Dis; 2019 Nov; 10(11):854. PubMed ID: 31699997 [TBL] [Abstract][Full Text] [Related]
11. DEPDC1B is a Novel Direct Target of B-Myb and Contributes to Malignant Progression and Immune Infiltration in Lung Adenocarcinoma. Zuo X; Wang D; Tao C; Dou X; Zhao Z; Zhang J; Huang S; Li Y; Zhang X; Bu Y; Wang Y Front Biosci (Landmark Ed); 2024 May; 29(6):204. PubMed ID: 38940035 [TBL] [Abstract][Full Text] [Related]
12. NSUN2 promotes lung adenocarcinoma progression through stabilizing PIK3R2 mRNA in an m Du X; Cheng C; Yang Y; Fan B; Wang P; Xia H; Ni X; Liu Q; Lu L; Wei L Mol Carcinog; 2024 May; 63(5):962-976. PubMed ID: 38411298 [TBL] [Abstract][Full Text] [Related]
13. SLC39A5 promotes lung adenocarcinoma cell proliferation by activating PI3K/AKT signaling. Liu Z; Hu Z; Cai X; Liu S Pathol Res Pract; 2021 Aug; 224():153541. PubMed ID: 34252710 [TBL] [Abstract][Full Text] [Related]
14. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3. Lan T; Li H; Zhang D; Xu L; Liu H; Hao X; Yan X; Liao H; Chen X; Xie K; Li J; Liao M; Huang J; Yuan K; Zeng Y; Wu H Mol Cancer; 2019 Dec; 18(1):186. PubMed ID: 31856849 [TBL] [Abstract][Full Text] [Related]
15. STRIP2 is regulated by the transcription factor Sp1 and promotes lung adenocarcinoma progression via activating the PI3K/AKT/mTOR/MYC signaling pathway. Pan J; Zhang Y; He L; Wu Y; Xiao W; Zhang J; Xu Y Genomics; 2024 Sep; 116(5):110923. PubMed ID: 39191354 [TBL] [Abstract][Full Text] [Related]
16. N Wang A; Zeng Y; Zhang W; Zhao J; Gao L; Li J; Zhu J; Liu Z; Huang JA Cell Mol Biol Lett; 2024 Aug; 29(1):106. PubMed ID: 39095708 [TBL] [Abstract][Full Text] [Related]
17. COL3A1-positive endothelial cells influence LUAD prognosis and regulate LUAD carcinogenesis by NCL-PI3K-AKT axis. Zhang M; Liang Y; Song P J Gene Med; 2024 Jan; 26(1):e3573. PubMed ID: 37547956 [TBL] [Abstract][Full Text] [Related]
18. Cancer/testis antigen LDHC promotes proliferation and metastasis by activating the PI3K/Akt/GSK-3β-signaling pathway and the in lung adenocarcinoma. Chen L; Wu Q; Xu X; Yang C; You J; Chen F; Zeng Y Exp Cell Res; 2021 Jan; 398(2):112414. PubMed ID: 33301764 [TBL] [Abstract][Full Text] [Related]
19. METTL3 exerts synergistic effects on m6A methylation and histone modification to regulate the function of VGF in lung adenocarcinoma. Shi K; Sa R; Dou L; Wu Y; Dong Z; Fu X; Yu H Clin Epigenetics; 2023 Sep; 15(1):153. PubMed ID: 37742030 [TBL] [Abstract][Full Text] [Related]
20. IGF2BP3 aggravates lung adenocarcinoma progression by modulation of PI3K/AKT signaling pathway. Chen X; Zhu X; Shen X; Liu Y; Fu W; Wang B Immunopharmacol Immunotoxicol; 2023 Jun; 45(3):370-377. PubMed ID: 36972188 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]